Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for EbolaGlobeNewsWire • 07/31/23
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023GlobeNewsWire • 07/25/23
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis UseGlobeNewsWire • 07/20/23
Why Is Emergent Biosolutions (EBS) Down 21.4% Since Last Earnings Report?Zacks Investment Research • 06/08/23
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian NordicGlobeNewsWire • 05/15/23
Bavarian Nordic Completes Acquisition of Travel Vaccine Portfolio from Emergent BioSolutionsGlobeNewsWire • 05/15/23
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDTGlobeNewsWire • 05/11/23
Emergent BioSolutions: A Turnaround In Sight With OTC Narcan Amidst Ongoing Opioid CrisisSeeking Alpha • 05/10/23
Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/23
Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 05/02/23
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023GlobeNewsWire • 04/19/23